Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.55 USD | -0.36% | +2.02% | -13.17% |
10:13am | Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma | MT |
15/05 | US FDA approves expanded use of Bristol's cancer cell therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.17% | 90.31B | |
+35.01% | 709B | |
+30.81% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.17% | 239B | |
+9.28% | 211B | |
-3.19% | 203B | |
+10.77% | 171B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers' Reblozyl Approved in EU as First-Line Treatment of Transfusion-Dependent Anemia